Moderna, Inc‘s MRNA biggest problem is no longer proving that its mRNA technology can work against cancer. Investors got that ...
Zacks Investment Research on MSN
MRNA stock soars 143% in a month: Time to buy, hold or sell?
Moderna MRNA shares have surged 143% in the past month, driven largely by recently announced positive late-stage results for ...
Moderna ( MRNA) climbed almost 9% on Thursday, closing at $158.07 after gaining $12.45 from the previous close. This came as the mRNA-medicine company continued its volatile trading following a ...
TREM2-targeted mRNA lipid nanoparticles may reprogramme the tumour microenvironment and improve responses to cancer immunotherapy.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, ...
Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results